Skip to main navigation

+44 (0)20 8154 4600
info@achillestx.com

Home
About Us
Science
Publications
Pipeline
- PIPELINE
- EXPANDED ACCESS
Investors & Media
CAREERS
Contact

Press Releases

Home
About Us
Science
Publications
Pipeline
- PIPELINE
- EXPANDED ACCESS
Investors & Media
CAREERS
Contact

Year

All News
2024
2023
2022
2021
2020
2019
2018
2017
2016

Aug 10 2021

Achilles Therapeutics Reports Second Quarter 2021 Financial Results and Recent Business Highlights

Read More +

Jul 1 2021

Achilles Therapeutics Enrolls First US Patient in Ongoing Phase I/IIa Study in Advanced Non-small Cell Lung Cancer

Read More +

Jun 4 2021

Achilles Therapeutics Details Phase I/IIa Clinical Trial Design of CHIRON in Patients with Advanced Non-Small Cell Lung Cancer at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

Read More +

May 11 2021

Achilles Therapeutics Reports First Quarter 2021 Financial Results and Recent Business Highlights

Read More +

May 6 2021

Achilles Therapeutics Receives Horizon 2020 Grant as Part of Neoantigen Consortium

Read More +

May 5 2021

Achilles Therapeutics to present at the BofA Securities 2021 Virtual Healthcare Conference

Read More +

May 3 2021

Achilles Therapeutics Appoints Julie O’Neill to Board of Directors and Markwin Velders, Ph.D. joins Scientific Advisory Board

Read More +

Apr 10 2021

Achilles Therapeutics Demonstrates cNeT Product Characterization and Post-Infusion Tracking in a Patient Case Study at the American Association for Cancer Research (AACR) 2021 Annual Meeting

Read More +

Apr 6 2021

Achilles Therapeutics Announces Closing of $175.5 million Initial Public Offering

Read More +

Mar 30 2021

Achilles Therapeutics Announces Pricing of Initial Public Offering

Read More +

Pagination

First page
Previous page
Page 1
Current page 2
Page 3
Next page
Last page

Print Page

RSS Feeds

Email Alerts

Contact IR

Home
About Us
Science
Publications
Pipeline
Investors & Media
Work with us
Contact

UK Headquarters:
Achilles Therapeutics plc
245 Hammersmith Road
London
W6 8PW, UK

US Headquarters:
Achilles Therapeutics US, Inc.
401 N. Broad Street
Suite M121
Philadelphia, PA 19108

+44 (0)20 8154 4600
info@achillestx.com

© Copyright - Achilles Therapeutics plc.

Achilles Therapeutics plc (13027460) is registered in England and Wales. The registered office is at 245 Hammersmith Road, London, W6 8PW.

Privacy & Cookie Policy

Terms & Conditions